DATA FROM TNFERADE ESOPHAGEAL CANCER STUDY PRESENTED AT 2010 ASCO GASTROINTESTINAL CANCER SYMPOSIUM
- Category: DNA RNA and Cells
- Published on Monday, 25 January 2010 02:00
- Hits: 1071
GenVec announced that data from the Company’s trial in esophageal cancer were presented at the American Society of Clinical Oncology’s 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010
GAITHERSBURG, MD, USA | January 22, 2010 | GenVec, Inc. (Nasdaq: GNVC) announced today that data from the Company’s trial in esophageal cancer were presented at the American Society of Clinical Oncology’s 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010.
The poster, titled, “Long term survival analysis of multicenter clinical trial using endoscopy (END) and endoscopic ultrasound (EUS) guided fine needle injection (FNI) of antitumor agent (TNFerade Biologic (TNF)) in patients with locally advanced esophageal cancer,” reports on updated efficacy and survival data. In the 24 patients receiving TNFerade in combination with chemoradiation, the median survival was 47.7 months. Median survival from other historical clinical trials in similar stage disease ranged from 9.7 to 34 months.
Research presented in the poster received a prestigious ASCO Foundation Merit Award. In addition, the poster received focused attention at the oral review session on esophageal cancer on January 22, 2010.
“This symposium brings together the greatest thought leaders in this area of oncology and we are pleased to be presenting this analysis at this event,” stated Mark Thornton, Ph.D., GenVec’s Senior Vice President of Product Development. “The encouraging increases in survival versus historical controls will warrant additional evaluation.”
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec’s lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including influenza, HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company’s various filings with the Securities and Exchange Commission.
SOURCE: GenVec Inc.